Cost-effectiveness of NT-proBNP-supported screening of chronic heart failure in patients with or without type 2 diabetes in Austria and Switzerland

Le résumé fourni par la source

Background: Heart failure (HF) is a clinical syndrome with a global burden.Signs and symptoms of HF are nonspecific and often shared with other conditions.The N-terminal prohormone of brain natriuretic peptide (NT-proBNP) serves as a useful biomarker for the diagnosis of HF not only in patients with acute symptoms but also in outpatients with an ambiguous clinical presentation.The aim of the analysis is to evaluate the cost-effectiveness of implementing NT-proBNP in the diagnostic algorithm in patients with/without type 2 diabetes mellitus (T2DM), compared with a diagnosis based primarily on clinical signs or symptoms from the perspective of the Austrian and Swiss healthcare system.Methods: A time-discrete Markov model was developed to simulate the effect/improvement (lifetimecosts, quality-adjusted life-years [QALYs], and life-years [LYs]) due to an NT-proBNP screening in undetected HF patients.Undetected HF patients are included in the model according to a distribution of New York Heart Association (NYHA) classes.The model considers disease progression by transition of NYHA classes.Undetected patients may remain undetected or be detected with the help of NT-proBNP or symptoms.Patients with known HF exhibit a slower disease progression.The probability of dying is influenced by the respective NYHA class.Direct costs (2021 e or CHF) were derived from published sources.QALYs, LYs, and costs were discounted (3% p.a.).Results: In the per-patient analysis (at age 60 over lifetime), the incremental cost-utility ratio (ICUR)/ QALY of NT-proBNP vs. no screening was e3,042 for HF patients in Austria.Considering the total cohort of undetected HF patients (n ¼ 9,377) with the corresponding age structure over a lifetime, the ICUR increases to e4,356.In Switzerland, the per-patient results show an ICUR of CHF 897.Considering the total cohort of undetected HF patients (n ¼ 6,826) the ICUR amounts to CHF 4,513.If indirect costs are considered, NT-proBNP screening becomes the dominant strategy in both countries.Conclusion: Overall, the analysis concludes that screening with NT-proBNP is a highly cost-effective or cost-saving diagnostic option for patients with HF, and a sensitivity analysis confirmed these findings.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.